Literature DB >> 19011046

Chronic insulin treatment suppresses PTP1B function, induces increased PDGF signaling, and amplifies neointima formation in the balloon-injured rat artery.

Qinghua Pu1, Yingzi Chang, Chunxiang Zhang, Yi Cai, Aviv Hassid.   

Abstract

We tested the hypothesis that hyperinsulinemia induces the suppression of protein tyrosine phosphatase 1B (PTP1B) function, leading to enhanced PDGF receptor (PDGFR) signaling and neointimal hyperplasia. Rats were implanted with insulin-releasing pellets or sham pellets. Blood glucose levels, insulin levels, food and water intake, body weights, and blood pressures were measured. Neointimal hyperplasia was assessed by computerized morphometry 14 days after carotid balloon injury. PTP1B protein expression in injured arteries was determined via Western blot analysis, whereas PTP1B activity was determined via an immunophosphatase assay. Serum insulin levels were two- to threefold greater in hyperinsulinemic rats, whereas systolic blood pressures, food and water intake, serum triglyceride levels, plasma cortisol levels, and urinary catecholamine levels were not affected. Fourteen days after injury, neointima-to-media area ratios were 0.89 +/- 0.23 and 1.35 +/- 0.22 in control and hyperinsulinemic rats, respectively (P < 0.01). PTP1B protein levels and total PTP1B activity in injured carotid arteries from the insulin-treated group were significantly decreased 7 or 14 days after injury, whereas PTP1B specific activity was decreased only 14 days after injury. These findings were associated with decreased PTP1B mRNA levels and increased PDGFR tyrosyl phosphorylation in insulin-treated rats. These observations support the hypothesis that hyperinsulinemia induces the suppression of PTP1B function, leading to enhanced PDGFR signaling and neointimal hyperplasia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19011046      PMCID: PMC2637774          DOI: 10.1152/ajpheart.00370.2008

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  57 in total

1.  Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF.

Authors:  G A Ferns; E W Raines; K H Sprugel; A S Motani; M A Reidy; R Ross
Journal:  Science       Date:  1991-09-06       Impact factor: 47.728

2.  The nontransmembrane tyrosine phosphatase PTP-1B localizes to the endoplasmic reticulum via its 35 amino acid C-terminal sequence.

Authors:  J V Frangioni; P H Beahm; V Shifrin; C A Jost; B G Neel
Journal:  Cell       Date:  1992-02-07       Impact factor: 41.582

3.  Sustained hyperinsulinemia increases arterial pressure in conscious rats.

Authors:  M W Brands; D A Hildebrandt; H L Mizelle; J E Hall
Journal:  Am J Physiol       Date:  1991-04

4.  Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor.

Authors:  V Lindner; M A Reidy
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-01       Impact factor: 11.205

5.  Corticotropin-releasing factor secretion increases in rat hypophysial portal blood during insulin-induced hypoglycemia.

Authors:  V Guillaume; M Grino; B Conte-Devolx; F Boudouresque; C Oliver
Journal:  Neuroendocrinology       Date:  1989-06       Impact factor: 4.914

6.  Osmotic loading of neutralizing antibodies demonstrates a role for protein-tyrosine phosphatase 1B in negative regulation of the insulin action pathway.

Authors:  F Ahmad; P M Li; J Meyerovitch; B J Goldstein
Journal:  J Biol Chem       Date:  1995-09-01       Impact factor: 5.157

7.  Chronic insulin treatment amplifies PDGF-induced motility in differentiated aortic smooth muscle cells by suppressing the expression and function of PTP1B.

Authors:  Daming Zhuang; Qinghua Pu; Bogdan Ceacareanu; Yingzi Chang; Madhulika Dixit; Aviv Hassid
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-05-02       Impact factor: 4.733

8.  Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome.

Authors:  E Ferrannini; S M Haffner; B D Mitchell; M P Stern
Journal:  Diabetologia       Date:  1991-06       Impact factor: 10.122

9.  Increased insulin responsiveness in vivo and in vitro consequent to induced hyperinsulinemia in the rat.

Authors:  E R Trimble; G C Weir; A Gjinovci; F Assimacopoulos-Jeannet; R Benzi; A E Renold
Journal:  Diabetes       Date:  1984-05       Impact factor: 9.461

10.  A ligand-induced conformational change in the Yersinia protein tyrosine phosphatase.

Authors:  H L Schubert; E B Fauman; J A Stuckey; J E Dixon; M A Saper
Journal:  Protein Sci       Date:  1995-09       Impact factor: 6.725

View more
  5 in total

1.  Mechanisms related to NO-induced motility in differentiated rat aortic smooth muscle cells.

Authors:  Qinghua Pu; Daming Zhuang; Shalini Thakran; Aviv Hassid
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-10-29       Impact factor: 4.733

2.  PDGF-induced vascular smooth muscle cell proliferation is associated with dysregulation of insulin receptor substrates.

Authors:  Yan Zhao; Swarajit K Biswas; Patrick H McNulty; Mark Kozak; John Y Jun; Lakshman Segar
Journal:  Am J Physiol Cell Physiol       Date:  2011-02-16       Impact factor: 4.249

Review 3.  The role of protein tyrosine phosphatase 1B (PTP1B) in the pathogenesis of type 2 diabetes mellitus and its complications.

Authors:  Maryam Teimouri; Hossein Hosseini; Zahra ArabSadeghabadi; Reyhaneh Babaei-Khorzoughi; Sattar Gorgani-Firuzjaee; Reza Meshkani
Journal:  J Physiol Biochem       Date:  2022-01-06       Impact factor: 4.158

Review 4.  Emerging drugs for the treatment of diabetic ulcers.

Authors:  Francesco Tecilazich; Thanh L Dinh; Aristidis Veves
Journal:  Expert Opin Emerg Drugs       Date:  2013-05-21       Impact factor: 4.191

5.  Adipose weight gain during chronic insulin treatment of mice results from changes in lipid storage without affecting de novo synthesis of palmitate.

Authors:  Henriette Frikke-Schmidt; Thomas Åskov Pedersen; Christian Fledelius; Grith Skytte Olsen; Marc Hellerstein
Journal:  PLoS One       Date:  2013-09-17       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.